

Agenda

- Introductions
- Evaluation of the Maryland EQIP Performance Year 1 Results
 - Dobson & DaVanzo Health Economics Consulting
- PY4 Enrollment Administrative Updates
- PY3 & PY4 Data Release Schedule
- PY5 Episodes Development
- EQIP Practice Transformation Grant
- Rebasing Discussion



Evaluation of the Maryland Episode Quality Improvement Program (EQIP)

PRESENTED TO: Maryland Health Services Cost Review Commission (HSCRC) EQIP Subgroup Meeting

01/17/2025

PRESENTED BY: Dobson DaVanzo and Associates, LLC (Dobson | DaVanzo)

PREPARED BY: Al Dobson, Ph.D., Sandra Agik, M.S., Michael Beins, M.S., and Seung Ouk Kim, Ph.D.



Dobson DaVanzo & Associates, LLC Vienna, VA 703.260.1760 www.dobsondavanzo.com

Presentation Overview

- Introduction
- Methodology
- Key Findings
- Conclusions and Next Steps
- Questions



Introduction



5

5

Introduction

• Study Objectives

- Dobson | DaVanzo was commissioned to review and present the results for the first performance year (PY1) of the Episode Quality Improvement Program (EQIP)
- We conducted analyses to replicate results calculated by HSCRC and conducted a literature review to compare EQIP results to the other bundled payment programs and assess how the choice of methodology may impact findings



Key Features of EQIP

Participation	 Voluntary participation for general and specialist physicians Entities must meet minimum episode volumes to be eligible*
Spending Targets	 Based on same entity's 2019 data trended forward using CMS PPS market basket and HSCRC update factors
Risk Adjustment	• No risk adjustment
Episodes	• Performance Year 1 included 15 Prometheus clinical episode categories across three clinical specialty categories: Orthopedics, Cardiology, and Gastroenterology
Risk Sharing	 Upside only risk Entities held accountable for dissavings by requirement to offset dissavings with future savings and program removal following two consecutive years of dissavings Participants must attain a minimum savings threshold of 3 percent before receiving shared savings
Shared Savings	 Portion of savings earned by entity is tiered based on historical performance on specific clinical episodes across the entire state Additional incentive payments based on performance on 3 quality measures

* To be eligible to participate in EQIP, the entity must be attributed 11 or more clinical episodes within each clinical episode category OR 50 or more episodes across all clinical episode categories in which they elect and are eligible to Description Desc



Methodology



Data and Approach

• Data

• We obtained episode level data on Medicare spending and utilization for the baseline and PY 1 periods from HMetrix



• Approach

- Dobson | DaVanzo replicated the methodology that HSCRC used to derive program savings
- We also conducted a literature review to compare EQIP PY1 results to other similar bundled payment programs



Analytic Methodology

- HCRC's methodology compared an entity's PY 1 spending to target costs set using 2019 baseline data trended forward
- Analytic steps are outline below:
 - <u>Step 1</u>: Calculate the Episode Target Price

Episode Target Price _{Category} = $\frac{Total Episode Costs at Baseline trended to PY 1 Prices}{Number of Episodes at Baseline}$

• <u>Step 2</u>: Calculate the Aggregate Target Price (ATP)

Aggregate Target Price = Sum (Episode Target Price Category **x** Volume of Episodes in PY Category)

• <u>Step 3</u>: Determine Performance Year Costs

Performance Year Costs = Sum (Episode Costs for all Episodes in Performance Year)

• <u>Step 4</u>: Determine Performance Year Savings

Performance Year Savings = Performance Year Costs - Aggregate Target Price (by entity)



Key Findings



Overall Savings

• EQIP results:

- Entities with positive savings saved approximately \$20 million , approximately 7.7% of target costs for entities showing positive savings (or 5.1% of total target costs)
- Savings for all entities totaled \$12 million (or 3% of total target costs)

Clinical Episode Categories	Number of Entities	Volume of Episodes	Aggregate Target Price	PY 1 Episode Payments	Total Savings	Savings Rate	Savings Per Episode
All Entities	50	37,758	\$397,464,832	\$385,701,806	\$11,763,026	3.0%	
Entities with Positive Savings	19	29,557	\$260,925,858	\$240,774,722	\$20,151,136	7.7%	\$682

Performance Year 1 Results Overall¹

<u>Comparison to other programs</u>:

- Formal evaluations of CMS' bundled payment initiatives have shown overall cost savings ranging from 3 to 5 percent²
 - For example, hospitals under BPCI Model 2 showed savings of 3.1%, while physician group practices achieved 4.9% savings



Distribution of Savings by Episode Category

EQIP Results:

- Orthopedics represented the largest share of episodes by percent of baseline spending and appeared to generate the largest savings
- In aggregate, in PY 1 only orthopedics episodes generated savings

• <u>Comparison to other programs</u>:

obson | DaVanzo

- Consistent with studies evaluating BPCI, procedural (surgical) episodes were more likely to generate savings^{1,2}
- One study showed that savings for medical episodes increased over time as hospitals continued participation in bundled payments—suggesting that with experience they may be increase savings³

Distribution of Savings by Clinical Episode Category⁴

Episode Name	Saviı	ngs Rate	Average Savings Per Episode
Acute Myocardial Infarction		-1.70%	(\$529)
CABG &/or Valve Procedures		-4.60%	(\$3,006)
Coronary Angioplasty		1.00%	\$267
Pacemaker / Defibrillator		3. <mark>90%</mark>	\$1,216
Total Cardiology		-0.30%	(\$105)
Colonoscopy		1.80%	\$20
Colorectal Resection		13.20%	(\$4,532)
Gall Bladder Surgery		-6.30%	(\$961)
Upper GI Endoscopy		3.60%	\$59
Total Gastroenterology		-1.80%	(\$35)
Hip Replacement & Hip Revision		7.90%	\$1,784
Hip/Pelvic Fracture		-8.60%	(\$2,935)
Knee Arthroscopy		8.50%	\$322
Knee Replacement & Knee Revision		9.40%	\$2,105
Lumbar Laminectomy		0.60%	\$88
Lumbar Spine Fusion		8.90%	\$4,642
Shoulder Replacement		-6.90%	(\$1,647)
Total Orthopedics		5.90%	\$1,419

1. CMS. (2022) Synthesis of Evaluation Results across 21 Medicare Models, 2012-2020.

- Finkelstein, A., Ji, Y., Mahoney, N., & Skinner, J. (2018). Mandatory Medicare bundled payment program for lower extremity joint replacement and discharge to institutional postacute care: interim analysis of the first year of a 5-year randomized trial. Jama, 320(9), 892-900.
- 3. Rolnick, J. A., Liao, J. M., Emanuel, E. J., Huang, Q., Ma, X., Shan, E. Z., ... & Navathe, A. S. (2020). Spending and quality after three



4. Savings do no reflect exclusion of episodes below MSR, as that is applied at an entity level



Distribution of Savings by Entity Size

EQIP Results:

 Practices with a higher volume of episodes (Quintile 1 and 2) were more likely to achieve positive savings compared to practices with lower volume of episodes that were less likely to generate positive savings (Quintile 4, and 5)



Comparison to other programs:

 Studies in the literature show similar trends. Under CJR, for example, hospitals that achieved savings tended to be larger (with more than 400 beds), with a higher volume of Medicare procedures¹



Post-Acute Care Utilization

EQIP program results:

• PY1 beneficiaries tended to use less SNF care, use slightly more home health and returned to the community (home) more often

Comparison of Percent of Discharges to Post-Acute Care in the Baseline

			•			
	Cardio	ology	Gastroen	terology	Orthopedics	
	Baseline Year	PY 1	Baseline Year	PY 1	Baseline Year	PY 1
Community	73.30%	73.30%	99.00%	98.90%	50.00%	54.20%
Home Health	15.30%	18.30%	0.80%	1.00%	32.30%	36.80%
Hospice	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%
Inpatient Hospital	3.60%	4.10%	0.00%	0.00%	2.80%	2.70%
Skilled Nursing Facility	7.70%	4.30%	0.20%	0.10%	14.80%	6.30%

Year vs. PY 1, by Setting

<u>Comparison to other programs:</u>

- Studies have shown that bundled payment savings are likely due to reductions in post-acute care costs
- One study found that approximately half of hospitals' savings stemmed from changes in the utilization of post-acute care¹



1. Glickman, A., Dinh, C., & Navathe, A. S. (2018). The current state of evidence on bundled payments. LDI issue brief, 22(3), 1-5.

Impact of Analytic Methodology on Estimated Savings

- 1. Savings calculated using target prices may be subject to bias due to self selection and other confounding factors—leading to savings that are over or understated
 - Quasi-experimental methods, such as differences-in-differences analyses that compare the spending of program participants pre- and postimplementation of the program to a comparison group of non-participants can lead to more accurate results
- 2. Lack of risk adjustment is less likely to impact savings given that EQIP uses the same entity's historical episode spend to calculate target price
 - A study found that risk adjustment may not be necessary when target episode prices were set using hospital historical spending but may be important when regional episode spending was used to calculate



 Ellimoottil, C., Ryan, A. M., Hou, H., Dupree, J., Hallstrom, B., & Miller, D. C. (2016). Medicare's New Bundled Payment For Joint Replacement May Penalize Hospitals That Treat Medically Complex Patients. Health affairs (Project Hope), 35(9), 1651–1657. https://doi.org/10.1377/hlthaff.2016.0263.

Impact of analytic methodology on Estimated savings (continued)

- **3.** No indication of selective participation despite voluntary nature of EQIP
 - Selective participation could bias program evaluation results if for example, participating providers are more efficient and thus more likely to generate savings
 - In the first phase of this project, we conducted analyses to compare EQIP participating and non-participating provider and patient characteristics in 2019 (the baseline year)
 - Results showed that participating providers were not any different in from non-participating providers both based on the provider characteristics and patient characteristics
- 4. Using 2019 data to calculate the target price, may not accurately reflect the case-mix increases and spend post-COVID-19 PHE



Questions





Dobson DaVanzo & Associates, LLC (Dobson | DaVanzo) is a health economics and policy consulting firm based in the Washington, D.C. metropolitan area

Contact information: (703) 260-1760 al.dobson@dobsondavanzo.com www.dobsondavanzo.com



19

19

PY 4: Administrative and Enrollment Updates



PY4 Enrollment Summary

EQIP entities enrolled:	128	
Total Care Partners:	3,362	
Specialties represented:	38	
Smallest Entity:	1 CP	
Largest Entity:	244 CPs	
Largest Entity:	244 CPs	

Clinical Episode Categories	Number of EQIP Entities
Allergy	26
Behavioral	13
Cardiology	20
Dermatology	9
Emergency Care	21
Gastroenterology	23
Ophthalmology	8
Orthopedics	70
Pulmonology	24
Rheumatology	10
Urology	18



21

PY4 Enrollment: CPA Compliance and Probation Status

- <u>Care Partner Arrangement</u>: As per the State and UMMC's Agreement with CMS, Infrastructure Payments may not be distributed to an "individual or entity other than a Care Partner with whom the Hospital has a fully executed written Care Partner Arrangement."
 - Care Partners who did not submit CPAs have been removed
- <u>PY3 Care Partner Eligibility</u>: Care Partners on Probation in PY3, who did not touch a claim during PY3 Q1-2 are no longer be eligible for PY4. Care Partners can re-enroll for PY5.
 - Email notifications were sent out on Friday 1/10/2025 to all the Entity POCs alerting them to which Care Partner is no longer eligible.

Please refer to the EQIP Entity Portal (EEP) for current Care Partner list including finalized care partner agreement status



Final Eligibility Audit and Probation Status

- <u>Volume Thresholds</u>: Due to the composite of final Care Partner lists, some entities may fall below threshold for certain episodes. For a single episode, threshold = 11 episodes in the baseline and across all episodes of participation, threshold = 50 episodes in the baseline
- <u>Care Partner Probation</u>: Care Partners who do NOT touch a claim in baseline are considered on probation and must touch a claim in PY4 q1-2 to be eligible for PY5.
- <u>Quality Metrics</u>: Entities will be notified if baseline quality metrics fall in the lowest decile in the state. Entities who do NOT meet minimum quality performance during PY4 q1-2 will be placed on quality probation for PY5.

Entities will be notified via email on their final status by Friday, January 24th



Data Release Schedule



EQIP Data Release

- All data in EEP and used for EQIP analyses derive from the Claim and Claim Line Feed (CCLF) file
- The EQIP Suite (EEP) publishes Final Completed Episode Data only
 - *Final Completed Episode Data*: Data for episode that has completed episode timeline and finalized after claims run out (approx. 90 days)
- PY3 uses the Prometheus Grouper which is run by Change Healthcare and released quarterly.
- Starting in PY4, the PACES grouper will be used and allows HSCRC/CRISP to release data monthly.
 - New Preliminary Trigger Beneficiary List will be available in the EQIP Portal



EEP - Tentative Release Date Schedule

PY3 Data (Prometheus)	Proposed Release Date
Episodes Ending Q3	March 2025
Episodes Ending Q4	June 2025

PY4 Data (PACES)	Proposed Release Date
Baseline PY4	February 2025
PY4 – Episodes Ending January	June 2025
PY4 – Episodes Ending February	July 2025
PY4 – Episodes Ending March	Aug 2025
PY4 – Episodes Ending April	Sep 2025
PY4 – Episodes Ending December	February 2026

Note: All release dates are proposed and subject to change





EQIP Data Timeline – PY4 Performance Data (sample 14-day episode)

Sample 14-day episode:



EQIP Data Timeline – PY4 Performance Data (sample 90-day episode)

Sample 90-day episode:



PY5 Episode Development



Performance Year Five (CY2026) Episode Development Process



Finalized PACES Episodes

Clinical Category	Episode Name	Clinical Category	Episode Name	Clinical Category	Episode Name	1
Alcohol Drug Use or	substance abuse alcohol		anal/rectal fissur/ulcer		diabetes	(
Induced Men	substance abuse other		Bariatric surgery		diabetic circulatory complications	
	anemia chronic		Cholecystectomy		diabetic ketoacidosis dka (acute)	(
Blood and Blood	aplastic anemia		cholecystitis (acute)		diabetic neuropathy	(
Forming Organs	neutropenia		cholecystitis (chronic)		diabetic retinopathy	(
	neutropenia (acute)		Colectomy	Endocr. Nutritional &	diabetic skin complications	
	1st/2nd degree burn	-	Colonoscopy	Metabolic	ds of lipoid metabolism	
Burns	deep 3rd degree burn, whole body nos		crohn's disease		hemochromatosis	
	abdominal aortic aneurysm		diverticulitis of colon		hyperosmolarity non-ketotic coma (acute)	(
	acute DVT extremity/NOS		diverticulosis of intestine(chronic)		Hyporlycemia (acute)	(
	acute myocardial infarction		FGD endoscopy		Obesity hypoventilation syndrome	(
	atrial fibrillation/flutter (chronic)		EBCP		osteonorosis	(
	AV fistula creation and revision	Digestive System	esonhageal varices (chronic)			
		Henatohiliary	esophagitis (chronic)		Cataract surgery for	(
	Cardiac catheterization	riepatobiliary	CEPD Surgery		combined rating and vitroous procedures	
	cor pulmonalo (acuto)		bend Surgery		configured retina and videous procedures	
	corputitionale (acute)		hepatitis b (acute)			
	neart failure (acute)		nepaulus b (chronic)			
	heart faiture (chronic)					
	nypertension complic, malig acute				eyelid neoplasm malignant (not melanoma)	
	nypertension essential (chronic)		pancreas transplant complications		floaters	
	hypertension secondary (chronic)		peptic ulcer(acute)		Glaucoma surgery	
	Insertion of permanent pacemaker/AICD		peptic ulcer(chronic)	Eve	macular degeneration	
	ischemic heart disease		Proctoscopy/Anoscopy		macular edema	
	Legrevascularization		Sigmoidoscopy		macular hole	
Circulatory System	Leg vein ablation		small bowel resection		macular pucker	
	Legvein angioplasty		upper gi bleeding - other(acute)		post-cataract ds	
	neck artery dissection/aneurysm		abscess, furuncle and carbuncle		retina procedures	
	Open heart valve surgery		acquired deformity of nose		Retina/choroid destructive therapy	
	Percutaneous cardiac intervention		cavernous sinus thrombosis		retinal detachment	
	pericarditis, inflammatory		CSF rhinorrhea		retinal tear	
	peripheral asvd		deviated nasal septum		vitrectomy	
	post-op hemorrhage/hematoma		diplopia		vitrious hemorrhage	
	pulmonary valve ds (chronic)		disorders of cranial nerve		anxiety ds (chronic)	
	thoracic aortic aneurysm		epistaxis		attention deficit hyperactivity disorder	$\circ \circ \circ \circ \circ$
	transcatheter (percutaneous) tricuspid valve repair		facial abscess		electroconvulsive shock treatment	
	transcatheter aortic valve repair	Ear Nose Mouth &	Laryngitis chronic		intentional self-harm	
	transcatheter aortic valve replacement	Lai, Nose, Pioutina	loss of vision, one eye		major depression acute - single episode	
	transcatheter mitral valve repair	Throat	nasal encephalocele		obsessive compulsive disorder	
	transcatheter mitral valve replacement		nasal septum hematoma	Mental Behavioral	other transient organic mental ds	
	transcatheter tricuspid valve repair		nasolacrimal duct injury	Health	post-traumatic stress disorder (PTSD)	
	venous insufficiency varicosities		optic neuritis		psychotic ds schizophrenia acute	
Newborn	developmental delay		oral thrush		psychotic ds schizophrenia chronic (chronic)	
Transplant	Liver transplant		orbital trauma		recurrent depression	
			other disorders of vocal cords or larynx		single manic episode	31 •
			sinus surgery		stress ds	
			sinusitis acute		transient organic psychosis/delirium	(i • • • • (
			sinusitis chronic			

Finalized PACES Episodes (cont.)

Clinical Category	Episode Name	Clinical Category	Episode Name	Clinical Category	Episode Name
	abnormal uterine bleeding		candida infection nos		airway lung neoplasm malignant
	breast biopsy		c-difficile colitis		benign neoplasm of uterus
	breast cyst		cellulitis, trunk and extremities		breast neoplasm malignant
	Breast reconstruction	Infontious Disease	human papilloma virus		carcinoma in situ cervix
	Colpopexy	Infectious Disease	intracranial and/or intraspinal abscess		colorectal neoplasm malignant
	Colporrhaphy		long COVID-19 (chronic)	Neoplasms and	ds of the spleen, neoplasm
	dysplasia of cervix		meningitis	Myeloproliferativ	graft vs. host
Female Reproductive	menopausal sx		oropharynx cellulitis/abscess		leukemia acute
System	neoplasm of uncertain behavior of uterus		amputation		leukemia chronic
	other conditions of the breast		aseptic necrosis		malignant neoplasm of uterus
	pelvic inflammatory disease/chronic pelvic pain		bone nos fx		Mastectomy
	pid & related		carpal tunnel surgery		neoplasm of uncertain behavior of ovary
	pre-menopausal		Cervical Fusion		acute ischemic stroke
	unspecified breast lumps		Cervical Replacement		Carotid Revascularization
	vaginal bleeding		Fracture/dislocation treatment arm/wrist/hand		cerebral edema/compression
	Appendectomy		Fracture/dislocation treatment knee		cerebrovascular disease, occlusive/nos
	hernia other abdominal		Fracture/dislocation treatment lower leg/ankle/foot		dementia
	nos foreign body		HIP Replacement	Nervous System	head trauma nos w intracranial ini
	repair diaphragmatic hernia	Musculoskeletal Syste & Connec	hip/femur/pelvis fracture repair		head trauma nos w/hemorrhg w/o intracranial ini
General	repair femoral hernia		ioint nos ganglion/cvst		parkinsons ds
	repair hernia other abdominal		Knee arthroscopy		quadriplegia
	Repair inguinal hernia		n knee int internal derangement (acute)		sleep apnea
	repair umbilical or ventral hernia		knee int internal derangmnt		surgical cns completn
	Repair ventral hernia		Knee replacement		transient ischemic attack
	acute kidney failure		low back pain		C-section
bladder ds nec/nos			Lumbar and sacral spine surgery OTHER		ectopic pregnancy/related poc
	bladder outlet obstruction		lumbar decompression		indications of pregnancy prior to delivery
	chronic kidney disease - dialysis dependent		lumbar fusion		Newborn
	chronic kidney disease - not dialysis dependent		osteoarthritis		newhorn complications
	dialysis		osteomvelitis nos	Pregnancy, Childbirth	ob/l&d complications
	kidnev anomaly		osteomyelitis nos (acute)	and Puerp	perinatal grwth ds - over 2500 grams
dney and Urinary Trac	tkidnev ini		naranlegia		nost-natal maternal complications
Diseas	Pevronie's disease		rheumatoid arthritis		prenatal maternal cmplctns
	Prostatectomy		Shoulder Arthroscopy/Tendon Benair		termination of pregnancy prior to delivery
	renal dial graft complication		trunk anomolies		Vaginal Delivery
	renal vascular ds		cutaneous abscee furuncle or carbuncle of foot		acute pulmonary embolism
	retrograde ejaculation		decubitus ulcer unspecified		acute uri simple
	TIIBP		insect hite		asthma (chronic)
	Lirinary endoscony		mohssurgery		chronic hronchitis
	uti	Skin, Subcutaneous	non-healing surgical wound	Respiratory System	cond
		Tissue and B	nos superficial abrasion		Idiopathic nulmonary fibrosis
		1	nos superficial hlister		Lung resection
		1	nos superficial contusion		reen distress syndrome
			superficial injury nos		เธรษุ นเรนธรร รังแนเป็นเด
			σαμετησιατητίμη τη που		

PY5 Episode Development

- We plan to leverage the extensive PACES catalogue to continue to add episodes for future performance years
 - A list of finalized PACES episodes was distributed in Nov
 - Stakeholders feedback requested to gauge episode interest and determine new development needs
- 88 PACES Episodes of Interest
- 9 New Episode Development Requests



Requested PACES Episodes

Clinical Category	short_name	Clinical Category	short_name	Clinical Category	short_name
Alcohol Drug Use or	substance abuse alcohol		diabetes		amputation
Induced Men	substance abuse other		diabetic circulatory complications		aseptic necrosis
	anemia chronic		diabetic ketoacidosis dka (acute)		bone nos fx
Blood and Blood Forming	aplastic anemia		diabetic neuropathy		carpal tunnel surgery
Organs	neutropenia		diabetic retinopathy		Cervical Fusion
	neutropenia (acute)	Endocr, Nutritional &	diabetic skin complications		Cervical Replacement
Burns	1st/2nd degree burn	Metabolic	ds of lipoid metabolism	Mucaulaskalatal	Fracture/dislocation treatment arm/wrist/hand
	atrial fibrillation/flutter (chronic)		hemochromatosis	System & Connoc	Fracture/dislocation treatment knee
	heart failure (chronic)		hyperosmolarity non-ketotic coma (acute)	System & Connec	Fracture/dislocation treatment lower leg/ankle/foot
	hypertension essential (chronic)		Hypoglycemia (acute)		joint nos ganglion/cyst
Circulatory System	pericarditis, inflammatory		Obesity hypoventilation syndrome		knee jnt internal derangement (acute)
Circulatory System	AV fistula creation and revision		osteoporosis		knee jnt internal derangmnt
	hypertension complic, malig acute		macular degeneration		osteomyelitis nos
	hypertension secondary (chronic)		macular hole		osteomyelitis nos (acute)
	Leg vein angioplasty	Evo	macular pucker		Lumbar and sacral spine surgery OTHER
	anal/rectal fissur/ulcer	Еуе	retinal tear		airway lung neoplasm malignant
	crohn's disease		vitrectomy		benign neoplasm of uterus
	diverticulitis of colon		Glaucoma surgery		breast neoplasm malignant
diverticulosis of intestine(chronic)		Female Reproductive	breast biopsy		carcinoma in situ cervix
Digestive System,	esophageal varices(chronic)	System	Breast reconstruction		colorectal neoplasm malignant
ператорнату	esophagitis (chronic)		Appendectomy	Neoplasms and	ds of the spleen, neoplasm
	Bariatric surgery	Conorol	Repair inguinal hernia	Myeloproliferativ	graft vs. host 📃 🔍
	small bowel resection	General	repair umbilical or ventral hernia		leukemia acute
	ERCP		Repair ventral hernia		leukemia chronic
For Ness Mouth 9 Threat	epistaxis	Kidney and Uninem Treet	acute kidney failure		malignant neoplasm of uterus
Edi, Nose, Mouth & Hilodt	sinusitis acute	Noney and Urinary Tract	chronic kidney disease - dialysis dependent		neoplasm of uncertain behavior of ovary
Pregnancy, Childbirth and	C-section	DISEdS	chronic kidney disease - not dialysis dependent		Mastectomy
Puerp	Vaginal Delivery	Mental Behavioral Health	n single manic episode		dementia O O O O
		Respiratory System	acute uri simple	Norvous System	parkinsons ds
				ivervous system	acute ischemic stroke

transient ischemic attack



Requested PACES Episodes

- HSCRC to do initial review of requests
- In certain cases, either program methodology or data file will not align with episode definition
 - CCLF contains Medicare claims for all Part A and Part B
 - The data does not include certain substance abuse claims
- Episode playbooks to be made available to requesting stakeholders



New Episode Development

Specialty	Episode(s) of Interest			
Allergy/Immunology	Urticaria			
	Alopecia			
	Atypical nevus (Abnormal mole check)			
Dermatology	Psoriasis			
	Skin Cancer			
	Vitiligo			
Digestive System, Hepatobiliary	inflamm bowel ds ulcerative colitis			
Kidney and Urinary Tract Disease	Kidney Stones/nephrolithiasis			
Palliative Medicine	Sickle Cell Disease			

- HSCRC sent new episode development list to PACES team to determine if any are in the PACES catalogue
 - All but two conditions have PACES episodes constructed, but may require validation
 - The remaining two will need to be build and will require input from 2-3 clinical experts
- CRISP to pull together a kickoff meeting with clinical experts to meet the PACES team to begin episode development



EQIP Practice Transformation Grant Program



EQIP Practice Transformation Grant (PTG) - Vendor Collaboration

•Selected Vendors: Carefully chosen based on expertise in practice transformation, data analytics, and value-based care models.

•Vendor Roles:

Provide tailored support for practices in the PTG Program.
Assist with data analytics, performance tracking, and reporting.
Offer training and resources for staff and operational improvements.
Guide practices through the transition to value-based care.

•Collaboration Goals:

Help practices enhance patient outcomes and operational efficiency.
Equip entities with tools and knowledge for long-term sustainability in the evolving healthcare landscape.

•Ongoing Support: Continuous vendor engagement to monitor progress, offer feedback, and refine transformation strategies.



Practice Transformation Grant Update

Vendor Selections:

- Finalized last week.
 - 29 Entities with 69 Practices will be participating.
- Communicating with selected vendors to finalize contracts.

Next Steps:

 Schedule kick-off meetings in alignment with baseline data release, late February 2025.



C

Consideration of Rebasing



HSCRC considering options for updating the EQIP baseline

- A change, if made, would apply to 2026
- Could be voluntary or mandatory; could apply to all episodes or only some specialties
- Current EQIP Baseline Period is 2019
- HSCRC working on modeling the impact, will share thinking and discuss in next subgroup.
- Reasons to Consider Updating the Baseline
 - **Outdated:** Baseline period will be 7 years old for performance year 5 (PY5).
 - **Provider churn:** Influx of new providers
 - EQIP requires that 75% of the providers participating have data from the baseline period.
 - There are other policy changes that could address this issue.
 - Availability of post pandemic data:
 - Data from 2022 onwards reflects the current healthcare delivery system, especially regarding service location mix.
 - Program design:
 - Reduce payments relative to site of service mix changes where there has been considerable change outside the program.
 - Ensure performance under Total Cost of Care (TCOC) model.
 - Evaluation results with matched cases and controls may highlight challenges with using outdated baseline.
 - AHEAD uses 2023 baseline

HSCRC recognizes that this is a potentially significant change and won't make any changes without substantial stakeholder input





Thank you!

